NCT03055715 is a clinical trial in Non Small Cell Lung Cancer Stage III, sponsored by Martin-Luther-Universität Halle-Wittenberg.

Who is sponsoring NCT03055715?

NCT03055715 is sponsored by Martin-Luther-Universität Halle-Wittenberg.

What condition does NCT03055715 study?

NCT03055715 studies Non Small Cell Lung Cancer Stage III.

Is NCT03055715 still recruiting?

NCT03055715 is currently completed. Last updated 2 May 2018.

Last reviewed 2018-05-02 · How we verify

NCT03055715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC

Completed Last updated 2 May 2018

What this trial tests

trial in Non Small Cell Lung Cancer Stage III in 346 participants. Completed in 1 April 2018.

Timeline

1 April 2017

Primary endpoint
1 April 2018

1 April 2018

Quick facts

Lead sponsor	Martin-Luther-Universität Halle-Wittenberg
Status	Completed
Study type	OBSERVATIONAL
Enrollment	346
Start date	1 April 2017
Primary completion	1 April 2018
Estimated completion	1 April 2018
Sites	22 locations across Belgium, Austria, Germany, Switzerland, Spain

Conditions studied

Non Small Cell Lung Cancer Stage III — all drugs for Non Small Cell Lung Cancer Stage III →

Sponsor

Martin-Luther-Universität Halle-Wittenberg — full company profile →

Who can join

Adults 18 to 100, any sex, with Non Small Cell Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to retrospectively monitor the 'gross tumor volume' (GTV) before initiation of radiotherapy and its changes during radiotherapy and to correlate them with retrospectively recorded patient data, as well as with prognostic and therapeutic outcome after definite radiotherapy of locally advanced NSCLC in stage UICC III.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
Ostheimer C, Mäurer M, Ebert N, Schmitt D, et al · · 2021 · cited 11× · PMID 33410959 · DOI 10.1007/s00066-020-01727-4
PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.
Mäurer M, Käsmann L, Fleischmann DF, Oertel M, et al · · 2022 · cited 7× · PMID 35139856 · DOI 10.1186/s13014-022-01997-5
Tumor volume change at radiation boost planning to estimate the response to chemoradiotherapy in stage III unresectable NSCLC (TORCH): a multicenter retrospective observational study.
Trommer S, Müller JA, Oertel M, Ehret F, et al · · 2025 · cited 1× · PMID 40029351 · DOI 10.1007/s00066-025-02374-3
Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
Ostheimer C, Mäurer M, Ebert N, Schmitt D, et al · · 2021 · cited 1× · PMID 33674905 · DOI 10.1007/s00066-021-01750-z
Tenth anniversary of the Young DEGRO Team Trial-reflecting on the past, shaping the future.
Ehret F, Oertel M, Rühle A. · · 2026 · PMID 40553141 · DOI 10.1007/s00066-025-02417-9

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer Stage III

Currently open trials in the same condition.

NCT04711330 — Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy · active not recruiting
NCT05382052 — Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment · active not recruiting
NCT04392505 — Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study · Phase 2 · active not recruiting

Other Martin-Luther-Universität Halle-Wittenberg trials

Trials by the same sponsor.

NCT07157280 — Quality Indicators in Obstetrics · not yet recruiting
NCT06901154 — Influence of the 3D-sonographic Representation of the Fetal Face on the Health-conscious Behavior of Pregnant Women · not yet recruiting
NCT05526963 — Reduction of Polypharmacy in Elderly People With Multiple Diseases · NA · recruiting
NCT07091097 — Multivisceral Oncological Resections Involving the Pancreas - An International Multicenter Study · completed
NCT05782530 — Prevalence of Tattoos and Piercings in Healthcare Using the Example of Obstetrics Workers · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03055715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Martin-Luther-Universität Halle-Wittenberg
Last refreshed: 2 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03055715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing